Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 3/20 | 0.40 |
| ▸ | DRD3 | P35462 | 2/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | GFER | P55789 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.37 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1268688 | 1.00 | EPHX1 (0.44) | EPHX1DRD2DRD3SCN9AOPRM1 | |
| SCHEMBL145280 | 1.00 | EPHX1 (0.44) | EPHX1DRD2DRD3SCN9AOPRM1 | |
| Hydrochloric Acid SCHEMBL2417195 | 0.98 | EPHX1 (0.43) | EPHX1DRD2DRD3SCN9AOPRM1 | |
| Hydrochloric Acid SCHEMBL2422106 | 0.98 | EPHX1 (0.43) | EPHX1DRD2DRD3SCN9AOPRM1 | |
| SCHEMBL16528516 | 0.95 | EPHX1 (0.47) | EPHX1DRD2DRD3SCN9AOPRM1 | |
| SCHEMBL487705 | 0.95 | EPHX1 (0.47) | EPHX1DRD2DRD3SCN9AOPRM1 | |
| SCHEMBL1062309 | 0.95 | EPHX1 (0.47) | EPHX1DRD2DRD3SCN9AOPRM1 | |
| Formic Acid Methyl Ester SCHEMBL28112828 | 0.92 | EPHX1 (0.39) | EPHX1DRD2DRD3SCN9AOPRM1 | |
| SCHEMBL1398833 | 0.89 | EPHX1 (0.44) | EPHX1DRD2TDP1GFERTSHR | |
| SCHEMBL18992238 | 0.89 | EPHX1 (0.44) | EPHX1DRD2TDP1GFERTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 162 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12466815-B2 | Carboxamide compounds and uses thereof | INCYTE CORPORATION (US) | 2025-11-11 | — | — | US | disclosed |
| EP-4619097-A1 | AUTOPHAGY INDUCING COMPOUNDS AND USES THEREOF | Samsara Therapeutics Inc. (US) | 2025-09-24 | — | — | EP | disclosed |
| WO-2025106477-A1 | NOVEL AUTOPHAGY INDUCING COMPOUNDS AND USES THEREOF | Samsara Therapeutics Inc. (US) | 2025-05-22 | — | — | WO | disclosed |
| CN-118619877-A | Oxalyl diamine derivatives and uses thereof | 中国科学院上海药物研究所 | 2024-09-10 | — | — | CN | disclosed |
| US-20240217989-A1 | Heteroaryl Fluoroalkenes As DGK Inhibitors | INCYTE CORPORATION | 2024-07-04 | — | — | US | disclosed |
| WO-2024107434-A1 | AUTOPHAGY INDUCING COMPOUNDS AND USES THEREOF | Samsara Therapeutics Inc. (US) | 2024-05-23 | — | — | WO | disclosed |
| WO-2024108100-A1 | HETEROARYL FLUOROALKENES AS DGK INHIBITORS | INCYTE CORPORATION (US) | 2024-05-23 | — | — | WO | disclosed |
| US-20240150326-A1 | CARBOXAMIDE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2024-05-09 | — | — | US | disclosed |
| US-20230312479-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2023-10-05 | — | — | US | disclosed |
| US-11731958-B2 | Carboxamide compounds and uses thereof | INCYTE CORPORATION (US) | 2023-08-22 | — | — | US | disclosed |
| WO-2005090344-A1 | NOVEL DICHLORO-PHENYL-PYRIDO [2,3-D] PYRIMIDINE DERIVATES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-09-29 | — | — | WO | disclosed |
| EP-1575925-A1 | NOVEL CARBOXAMIDES, THE PRODUCTION AND USE THEREOF AS MEDICAMENTS | Boehringer Ingelheim International GmbH (DE) | 2005-09-21 | — | — | EP | disclosed |
| WO-2004092171-A2 | TRIAZOLO[1,5-A]PYRIMIDINES AND PYRAZOLO[1,5-A]PYRIMIDINES USEFUL AS A2A ADENOSIN E RECEPTOR ANTAGONISTS | BIOGEN IDEC MA INC. (US) | 2004-10-28 | — | — | WO | disclosed |
| WO-2004092170-A2 | TRIAZOLOTRIAZINES AND PYRAZOLOTRIAZINES USEFUL AS A2A ADENOSINE RECEPTOR ANTAGON ISTS | BIOGEN IDEC MA INC. (US) | 2004-10-28 | — | — | WO | disclosed |
| WO-2004092172-A2 | TRIAZOLO[1,5-C]PYRIMIDINES AND PYRAZOLO[1,5-C]PYRIMIDINES USEFUL AS A2A ADENOSIN E RECEPTOR ANTAGONISTS | BIOGEN IDEC MA INC. (US) | 2004-10-28 | — | — | WO | disclosed |
| US-20040176603-A1 | Substituted nitrogen-containing heterobicycles, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-09-09 | — | — | US | disclosed |
| WO-2004056784-A1 | NOVEL CARBOXAMIDES, THE PRODUCTION AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-07-08 | — | — | WO | disclosed |
| EP-0871628-A1 | QUINOLIZINONE TYPE COMPOUNDS | Abbott Laboratories (US) | 1998-10-21 | — | — | EP | disclosed |
| US-5726182-A | TREATMENT OF BACTERIAL INFECTIONS | ABBOTT LABORATORIES (US) | 1998-03-10 | — | — | US | disclosed |
| WO-1996039407-A1 | QUINOLIZINONE TYPE COMPOUNDS | ABBOTT LABORATORIES (US) | 1996-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230312479-A1 | NOVEL AMINO ACID DERIVATIVES | DNPEP, BCAT1, ANPEP | EPHX1 4836/4885DRD2 3574/4885DRD3 3412/4885 |
| US-11731958-B2 | Carboxamide compounds and uses thereof | PCK1, PHKG2, PHKG1 | EPHX1 1708/4885DRD2 4842/4885DRD3 4823/4885 |
| US-20040176603-A1 | Substituted nitrogen-containing heterobicycles, the preparation thereof and their use as pharmaceutical compositions | F11, F12, F2 | EPHX1 1415/4885DRD2 2845/4885DRD3 1754/4885 |
| US-20240150326-A1 | CARBOXAMIDE COMPOUNDS AND USES THEREOF | PCK1, PHKG2, PHKG1 | EPHX1 1708/4885DRD2 4842/4885DRD3 4823/4885 |
| US-12466815-B2 | Carboxamide compounds and uses thereof | PCK1, PHKG2, PHKG1 | EPHX1 1708/4885DRD2 4842/4885DRD3 4823/4885 |
| US-20240217989-A1 | Heteroaryl Fluoroalkenes As DGK Inhibitors | DGKA, DGKG, DGKK | EPHX1 1581/4885DRD2 2194/4885DRD3 2098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.